Cortexin is a complex neuropeptide preparation derived from the cerebral cortex of cattle and pigs, containing a mixture of low-molecular-weight polypeptides (up to 10 kDa), amino acids, vitamins, and trace minerals. Unlike single-sequence peptides, it is a multi-component extract. Registered as a pharmaceutical in Russia and CIS countries since 1999 for neurological conditions including ischemic stroke, TBI, and cognitive impairment. Not approved by FDA, EMA, or other Western regulatory agencies. Research demonstrates multi-target neuroprotective activity including caspase-8 inhibition, antioxidant defense, and BDNF modulation.
Category: Neuroprotection / Nootropic. Evidence rating: D (animal/preclinical only).
Clinical status: Registered pharmaceutical in Russia/CIS since 1999. Extensive clinical use in Russian neurology. No Western regulatory approval or clinical trials meeting international standards.
Cortexin acts through multiple convergent neuroprotective pathways: (1) Anti-apoptotic activity via inhibition of brain caspase-8, a key initiator of extrinsic apoptosis (Yakovlev, Biomeditsinskaia Khimiia 2017, PMID: 28251948); (2) Antioxidant defense through both direct radical scavenging and…
Safety considerations: Substantial clinical safety record through pharmaceutical use in Russia/CIS since 1999; Most common adverse effect: injection site reactions (pain, redness, swelling) from IM administration; Rare allergic/hypersensitivity reactions reported (consistent with animal-derived protein composition).
Reviewed by the PeptideAtlas Editorial Team.
| Molecular weight | Variable (mixture, up to 10,000 Da) |
|---|---|
| Production method | bioactive |
| Anti-doping status | not-listed |
| US regulatory status | Not FDA-approved. No IND application. |
No. Cortexin is a complex mixture of low-molecular-weight polypeptides (up to 10 kDa), amino acids, vitamins, and trace minerals extracted from bovine/porcine cerebral cortex. This multi-component nature distinguishes it from single-sequence peptides.
Both are animal-derived brain peptide preparations. Cerebrolysin is derived from porcine brain and has more extensive Western clinical trial data including large stroke trials. Cortexin is derived from cerebral cortex specifically and has broader Russian clinical use. Preclinical comparisons show similar efficacy.
It has been used clinically in Russia since 1999 with a generally favorable safety record. However, no Western-standard comprehensive safety assessment exists. The animal-derived nature raises theoretical prion concerns, and allergic reactions are possible.
The clinical evidence is predominantly in Russian-language journals and does not meet Western regulatory trial design standards (adequate randomization, blinding, power). Additionally, animal-derived brain extracts face higher regulatory scrutiny in Western markets due to prion disease concerns.